Prescribing information

About the molecule and how it works.

A specifically engineered anti-VEGF

A single-chain antibody fragment aims to facilitate deeper penetration of active molecules than larger molecules within tissue.1

Diagram with more information about the Beovu molecule

The molecule

Beovu has a high affinity to VEGF-A isoforms1 and can inhibit VEGF through prevention of the ligand-receptor interaction.

VEGF, vascular endothelial growth factor; VEGF-A, vascular endothelial growth factor A.

References

  1. Gaudreault J et al. Invest Ophthalmol Vis Sci. 2012; 53: 3025.
  2. Beovu Summary of Product Characteristics, 2020.
  3. Yannuzzi NA, Freund KB. Clin Ophthalmol. 2019; 13: 1323–1329.
BEO20-C039k June 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]